Nabriva Therapeutics PLC – (NASDAQ:NBRV) – Research analysts at Wedbush increased their Q3 2019 earnings per share estimates for shares of Nabriva Therapeutics in a report issued on Wednesday, May 1st, Zacks Investment Research reports. Wedbush analyst R. Driscoll now forecasts that the biotechnology company will earn ($0.26) per share for the quarter, up from their prior forecast of ($0.51). Wedbush also issued estimates for Nabriva Therapeutics’ Q4 2019 earnings at ($0.27) EPS, FY2019 earnings at ($1.18) EPS, FY2020 earnings at ($1.14) EPS, FY2021 earnings at ($0.75) EPS, FY2022 earnings at ($0.31) EPS and FY2023 earnings at $0.36 EPS.
Several other equities analysts have also issued reports on NBRV. Zacks Investment Research lowered Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 30th. BidaskClub raised Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 5th. Northland Securities reissued a “buy” rating and issued a $12.50 price target on shares of Nabriva Therapeutics in a research note on Tuesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Nabriva Therapeutics in a research note on Wednesday, March 13th. Finally, Gabelli downgraded Nabriva Therapeutics from a “buy” rating to a “sell” rating and set a $2.56 price objective for the company. in a report on Wednesday, March 27th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. Nabriva Therapeutics has a consensus rating of “Buy” and a consensus target price of $8.25.
Nabriva Therapeutics (NASDAQ:NBRV) last issued its quarterly earnings results on Friday, May 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.03. Nabriva Therapeutics had a negative return on equity of 119.75% and a negative net margin of 3,194.72%. The firm had revenue of $1.70 million for the quarter, compared to analyst estimates of $0.56 million.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in NBRV. Jane Street Group LLC bought a new stake in shares of Nabriva Therapeutics during the fourth quarter valued at approximately $29,000. HRT Financial LLC bought a new stake in Nabriva Therapeutics during the fourth quarter worth $31,000. Two Sigma Advisers LP bought a new stake in Nabriva Therapeutics during the fourth quarter worth $37,000. Parametric Portfolio Associates LLC grew its holdings in Nabriva Therapeutics by 82.2% during the first quarter. Parametric Portfolio Associates LLC now owns 18,616 shares of the biotechnology company’s stock worth $45,000 after buying an additional 8,396 shares in the last quarter. Finally, Paloma Partners Management Co bought a new stake in Nabriva Therapeutics during the fourth quarter worth $54,000. Hedge funds and other institutional investors own 4.18% of the company’s stock.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Read More: What is a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.